Oral lesions in HIV and HCV co-infected individuals in HAART era

J Oral Pathol Med. 2008 Sep;37(8):468-74. doi: 10.1111/j.1600-0714.2008.00647.x. Epub 2008 Feb 19.

Abstract

Background: During recent years, a new population of HIV and HCV co-infected subjects has emerged presenting particular oral problems. The aim of our study was to determine the prevalence of oral lesions in HIV+ subjects and HIV and HCV co-infected subjects, to assess whether co-infection is a risk factor for the presence of oral lesions.

Methods: 200 HIV+ subjects were consecutively enrolled, divided into two groups: Group 1 (130 HIV+ subjects) and Group 2 (70 HIV-HCV co-infected subjects) and visited by two oral medicine specialists. Epidemiological, laboratory and clinical parameters were gathered to determine the possible risk factors for oral lesions.

Results: 52 on 200 subjects (26%) presented oral lesions: in Group 1, 25 on 130 subjects (19.23%) presented oral lesions, whereas in Group 2, 27 on 70 subjects (38.57%) presented oral lesions. Multivariate analysis showed that the following variables are statistically associated with the presence of oral lesions: HIV-HCV co-infection (OR = 2.32; 95% CI = 1.01-5.33: P < 0.05) and the use of drugs for the treatment of systemic diseases not associated with HIV (OR = 4.34; 95% CI = 1.78-5.33: P = 0.005).

Conclusions: It is possible to assess, on the basis of our results, that co-infected patients are more prone than HIV mono-infected patients to develop oral lesions and thus should undergo strict oral medicine monitoring.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alcohol Drinking
  • Antiretroviral Therapy, Highly Active*
  • Antiviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • Coitus
  • Disease Susceptibility
  • Feeding Behavior
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / transmission
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy
  • Hepatitis C / transmission
  • Humans
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Mouth Diseases / etiology*
  • Mouthwashes / therapeutic use
  • Ribavirin / therapeutic use
  • Risk Factors
  • Smoking
  • Substance Abuse, Intravenous
  • Time Factors
  • Viral Load
  • Young Adult

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Mouthwashes
  • Ribavirin